ImmuCell (NASDAQ:ICCC) Share Price Passes Above 200-Day Moving Average - Here's Why

Key Points

• ImmuCell shares have surpassed their 200-day moving average, rising to $6.25 from a previous average of $5.93, reflecting a 4.9% increase during the trading session.
• The company reported a quarterly revenue of $6.45 million with earnings per share of $0.06, indicating a return on equity of 6.25% and a net margin of 6.23%.
• Institutional investors are actively investing in ImmuCell, with Northern Trust Corp increasing its stake by 51.0%, indicating growing interest in the biopharmaceutical sector.

Shares of ImmuCell Corporation (NASDAQ:ICCC - Get Free Report) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $5.93 and traded as high as $6.25. ImmuCell shares last traded at $6.25, with a volume of 6,898 shares trading hands.

ImmuCell Stock Up 4.9%

The company has a debt-to-equity ratio of 0.28, a current ratio of 3.85 and a quick ratio of 1.99. The firm has a market cap of $56.56 million, a PE ratio of 32.90 and a beta of 0.29. The business has a fifty day moving average price of $6.30 and a two-hundred day moving average price of $5.93.

ImmuCell (NASDAQ:ICCC - Get Free Report) last issued its quarterly earnings results on Thursday, August 14th. The biotechnology company reported $0.06 earnings per share for the quarter. ImmuCell had a return on equity of 6.25% and a net margin of 6.23%.The business had revenue of $6.45 million for the quarter.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of ICCC. Northern Trust Corp grew its stake in ImmuCell by 51.0% in the fourth quarter. Northern Trust Corp now owns 44,374 shares of the biotechnology company's stock valued at $229,000 after purchasing an additional 14,982 shares in the last quarter. Citadel Advisors LLC purchased a new position in ImmuCell in the fourth quarter valued at about $149,000. Finally, Geode Capital Management LLC grew its stake in ImmuCell by 4.2% in the second quarter. Geode Capital Management LLC now owns 71,852 shares of the biotechnology company's stock valued at $500,000 after purchasing an additional 2,907 shares in the last quarter. Hedge funds and other institutional investors own 13.47% of the company's stock.

About ImmuCell

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.